BioSpace News Archive

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the long-term data from the MIRROR randomized controlled clinical trial of KRYSTEXXA® (pegloticase) injection with methotrexate, a commonly used immunomodulator, in ACR Open Rheumatology [https://doi.org/10.1002/acr2.11578].

Women seeking to start or expand a family can now access the Proov Confirm PdG home collection kit for assessing fertility through questhealth.com.

South Rampart Pharma, Inc. (“South Rampart” or the “Company”) today announced that the China National Intellectual Property Administration (CNIPA) has granted the Company a new patent covering the composition of matter of SRP-001, South Rampart’s novel, non-opioid new chemical entity that avoids the liver toxicity associated with acetaminophen.

Altamira Therapeutics Ltd. announced today the pricing of a public offering of 11,111,112 common shares (or pre-funded warrants in lieu thereof) accompanied by common warrants to purchase up to 11,111,112 common shares, at a combined public offering price of $0.45 per share.

Phil Inc. , a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with RedHill Biopharma (Nasdaq: RDHL) (‘RedHill’) to make its medication Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) available via the PhilRx Patient Access Platform.

Myriad Genetics, Inc. announced that it has established a new $90 million asset-based credit facility with JPMorgan Chase Bank, N.A. as administrative agent and issuing bank, and the other lender parties thereto consisting of Wells Fargo Bank, N.A. and Bank of America, N.A.

Hillstream BioPharma, Inc. today announced the signing of an exclusive agreement with Applied Biomedical Science Institute (ABSI) to license technology for human antibodies targeting novel HER2 and HER3 Conformational Epitopes.

Stryker announced the launch of its Ortho Q Guidance system, the only fully autonomous system in the industry, easily controlled by the surgeon from the sterile field.

Evofem Biosciences, Inc. , (OTCQB: EVFM) (the “Company”) today announced that Saundra Pelletier , Chief Executive Officer, and Amy Raskopf , Senior Vice President, Investor Relations of Evofem, will participate in the Virtual Investor Summer Spotlight on Wednesday, July 12, 2023 at 4:00 p.m. ET.

Moleculin Biotech, Inc. today announced that Walter Klemp , President and Chief Executive Officer and Jon Foster, Executive VP & Chief Financial Officer of Moleculin, will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 3:00 PM ET.